EASI p-EASI: Utilizing a combination of serum biomarkers offers an objective measurement tool for disease severity in atopic dermatitis patients

Judith L. Thijs; Julia Drylewicz; Renée Fiechter; Ian Strickland; Matthew A. Sleeman; Athula Herath; Richard D. May; Catharina A.F.M. Bruijnzeel-Koomen; Edward F. Knol; Barbara Giovannone; Marjolein S. de Bruin-Weller; Stefan Nierkens; Dirk Jan Hijnen

doi:10.1016/j.jaci.2017.06.046

EASI p-EASI: Utilizing a combination of serum biomarkers offers an objective measurement tool for disease severity in atopic dermatitis patients

Judith L. Thijs, Julia Drylewicz, Renée Fiechter, Ian Strickland, Matthew A. Sleeman, Athula Herath, Richard D. May, Catharina A.F.M. Bruijnzeel-Koomen, Edward F. Knol, Barbara Giovannone, Marjolein S. de Bruin-Weller, Stefan Nierkens, Dirk Jan Hijnen^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

28 Citations (Scopus)

Original language	English
Pages (from-to)	1703-1705
Number of pages	3
Journal	Journal of Allergy and Clinical Immunology
Volume	140
Issue number	6
DOIs	https://doi.org/10.1016/j.jaci.2017.06.046
Publication status	Published - Dec 2017
Externally published	Yes

Bibliographical note

Funding Information:
The study was supported in part by MedImmune.

Funding Information:
Disclosure of potential conflict of interest: I. Strickland and A. Herath are former employees of MedImmune. M. A. Sleeman was employed by MedImmune Ltd at the time of this study and previously held shares in AstraZeneca. R. D. May is employed by MedImmune and receives stock/stock options as part of his compensation. C. A. F. M. Bruijnzeel-Koomen has received grants from MedImmune and UMC Urtrecht (grant no. CW435174). M. S. de Bruin-Weller has board memberships with Regeneron/Sanofi and AbbVie, has consultant arrangements with Regeneron/Sanofi, and has received grants from Regeneron/Sanofi. D. J. Hijnen has received grants from MedImmune and UMC Urtrecht (grant no. CW435174) and Regeneron and is on advisory boards for MedImmune and Novartis. The rest of the authors declare that they have no relevant conflicts of interest.

Access to Document

10.1016/j.jaci.2017.06.046

Cite this

Thijs, J. L., Drylewicz, J., Fiechter, R., Strickland, I., Sleeman, M. A., Herath, A., May, R. D., Bruijnzeel-Koomen, C. A. F. M., Knol, E. F., Giovannone, B., de Bruin-Weller, M. S., Nierkens, S., & Hijnen, D. J. (2017). EASI p-EASI: Utilizing a combination of serum biomarkers offers an objective measurement tool for disease severity in atopic dermatitis patients. Journal of Allergy and Clinical Immunology, 140(6), 1703-1705. https://doi.org/10.1016/j.jaci.2017.06.046

@article{3e5c353c1d414b2ba9b8eff89293bbb2,

title = "EASI p-EASI: Utilizing a combination of serum biomarkers offers an objective measurement tool for disease severity in atopic dermatitis patients",

author = "Thijs, {Judith L.} and Julia Drylewicz and Ren{\'e}e Fiechter and Ian Strickland and Sleeman, {Matthew A.} and Athula Herath and May, {Richard D.} and Bruijnzeel-Koomen, {Catharina A.F.M.} and Knol, {Edward F.} and Barbara Giovannone and {de Bruin-Weller}, {Marjolein S.} and Stefan Nierkens and Hijnen, {Dirk Jan}",

note = "Funding Information: The study was supported in part by MedImmune. Funding Information: Disclosure of potential conflict of interest: I. Strickland and A. Herath are former employees of MedImmune. M. A. Sleeman was employed by MedImmune Ltd at the time of this study and previously held shares in AstraZeneca. R. D. May is employed by MedImmune and receives stock/stock options as part of his compensation. C. A. F. M. Bruijnzeel-Koomen has received grants from MedImmune and UMC Urtrecht (grant no. CW435174). M. S. de Bruin-Weller has board memberships with Regeneron/Sanofi and AbbVie, has consultant arrangements with Regeneron/Sanofi, and has received grants from Regeneron/Sanofi. D. J. Hijnen has received grants from MedImmune and UMC Urtrecht (grant no. CW435174) and Regeneron and is on advisory boards for MedImmune and Novartis. The rest of the authors declare that they have no relevant conflicts of interest. ",

year = "2017",

month = dec,

doi = "10.1016/j.jaci.2017.06.046",

language = "English",

volume = "140",

pages = "1703--1705",

journal = "Journal of Allergy and Clinical Immunology",

issn = "0091-6749",

publisher = "Elsevier Inc.",

number = "6",

}

Thijs, JL, Drylewicz, J, Fiechter, R, Strickland, I, Sleeman, MA, Herath, A, May, RD, Bruijnzeel-Koomen, CAFM, Knol, EF, Giovannone, B, de Bruin-Weller, MS, Nierkens, S & Hijnen, DJ 2017, 'EASI p-EASI: Utilizing a combination of serum biomarkers offers an objective measurement tool for disease severity in atopic dermatitis patients', Journal of Allergy and Clinical Immunology, vol. 140, no. 6, pp. 1703-1705. https://doi.org/10.1016/j.jaci.2017.06.046

EASI p-EASI: Utilizing a combination of serum biomarkers offers an objective measurement tool for disease severity in atopic dermatitis patients. / Thijs, Judith L.; Drylewicz, Julia; Fiechter, Renée et al.
In: Journal of Allergy and Clinical Immunology, Vol. 140, No. 6, 12.2017, p. 1703-1705.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - EASI p-EASI

T2 - Utilizing a combination of serum biomarkers offers an objective measurement tool for disease severity in atopic dermatitis patients

AU - Thijs, Judith L.

AU - Drylewicz, Julia

AU - Fiechter, Renée

AU - Strickland, Ian

AU - Sleeman, Matthew A.

AU - Herath, Athula

AU - May, Richard D.

AU - Bruijnzeel-Koomen, Catharina A.F.M.

AU - Knol, Edward F.

AU - Giovannone, Barbara

AU - de Bruin-Weller, Marjolein S.

AU - Nierkens, Stefan

AU - Hijnen, Dirk Jan

N1 - Funding Information: The study was supported in part by MedImmune. Funding Information: Disclosure of potential conflict of interest: I. Strickland and A. Herath are former employees of MedImmune. M. A. Sleeman was employed by MedImmune Ltd at the time of this study and previously held shares in AstraZeneca. R. D. May is employed by MedImmune and receives stock/stock options as part of his compensation. C. A. F. M. Bruijnzeel-Koomen has received grants from MedImmune and UMC Urtrecht (grant no. CW435174). M. S. de Bruin-Weller has board memberships with Regeneron/Sanofi and AbbVie, has consultant arrangements with Regeneron/Sanofi, and has received grants from Regeneron/Sanofi. D. J. Hijnen has received grants from MedImmune and UMC Urtrecht (grant no. CW435174) and Regeneron and is on advisory boards for MedImmune and Novartis. The rest of the authors declare that they have no relevant conflicts of interest.

PY - 2017/12

Y1 - 2017/12

UR - http://www.scopus.com/inward/record.url?scp=85029224607&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2017.06.046

DO - 10.1016/j.jaci.2017.06.046

M3 - Article

C2 - 28823810

AN - SCOPUS:85029224607

SN - 0091-6749

VL - 140

SP - 1703

EP - 1705

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

IS - 6

ER -

EASI p-EASI: Utilizing a combination of serum biomarkers offers an objective measurement tool for disease severity in atopic dermatitis patients

Bibliographical note

Access to Document

Other files and links

Cite this